drug
dexamethasone LA
Marketedupdated 5mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 75 approved and 174 investigational indications.
indications
investigational
Diabetic Macular Edema
all catalysts(14)
approval · 14
Jun 17, 2009
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Aug 31, 2010
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 24, 2010
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 24, 2012
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 7, 2012
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 7, 2014
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Jun 28, 2014
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 26, 2014
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 5, 2016
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
May 15, 2018
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Oct 21, 2020
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Dec 19, 2022
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Mar 11, 2026
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
TBD
approval
$ABBV266.28+0.73%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Trials studying dexamethasone LA
- phase2Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
- phase3A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- phase3A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- phase2Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- phase2EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 7, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Apr 26, 2041method-of-use (U-1680)US 12144889
- Jun 23, 2039formulationUS 11097061
- Nov 16, 2037method-of-use (U-3455)US 11458041
- Oct 7, 2036method-of-use (U-3455)US 12150896
- Jun 22, 2034method-of-use (U-2340)US 10022502
- May 23, 2034method-of-use (U-2340)US 10028965
- May 23, 2034formulationUS 10159683
- May 11, 2032formulationUS 10799642
- May 14, 2030formulationUS 84096063.6y
- Feb 12, 2030method-of-use (U-2487)US 85630273.4y
FDA exclusivities (1)
- Apr 7, 2028NPPNew Product (3y)1.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that